Finally, we retrieved five diagnostic biomarkers from the DGIdb database and obtained potential drugs associated with GATA3 and KLF4 for the treatment of NAFLD. This evidence concerns the gene KLF4 and metabolic dysfunction-associated steatotic liver disease.